Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Begins Dosing Patients in Phase I Cancer Drug Study

Premium

Tekmira Pharmaceuticals said late last month that it has begun dosing patients in a phase I study of its cancer drug TKM-PLK1.

The drug targets polo-like kinase 1, or PLK1, a cell cycle protein involved in tumor cell proliferation and a validated oncology target, the company said.

The trial is an open label, multi-dose, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of TKM-PLK1, and to determine the drug's maximum tolerated dose. It will trial will enroll up to 52 patients with advanced solid tumors.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.